WTO Waiver Spurs In-House Fears of Broader Deals

Director Jorge A. Goldstein, Ph.D., was quoted in the article “WTO Waiver Spurs In-House Fears of Broader Deals,” published by Managing IP. From the article:

“The World Trade Organization’s COVID patent waiver hasn’t torpedoed pharma’s business model just yet, nor has it solved vaccine inequality, but it has raised concerns among counsel in innovator pharma businesses over the world’s respect for intellectual property in the long term.

The WTO agreed to a patent waiver for COVID vaccines on June 16 and stated that members would decide whether the IP suspension deal should be extended to cover COVID diagnostics and therapeutics within six months.”